Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.

M, He; Q, Li; R, Zou; J, Shen; W, Fang; G, Tan; Y, Zhou; X, Wu; L, Xu; W, Wei; Y, Le; Z, Zhou; M, Zhao; Y, Guo; R, Guo; M, Chen; M, Shi

doi:10.1001/jamaoncol.2019.0250

Public

Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.

Shared by NobleBlocks on Jul 1, 2019 • 12:00 AM UTC

Authors:

He M

Li Q

Zou R

Abstract

<h4>Importance</h4>Sorafenib is the first-line treatment for hepatocellular carcinoma with portal vein invasion; however, it has shown unsatisfactory survival benefit. Sorafenib plus hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil, and leucovorin (FOLFOX) has shown promisi...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!